KRAS and lung carcinoma: Because mutant KRAS-driven lung cancers are largely resistant to therapy, ISR inhibitors like ISRIB are promising agents for the treatment of this common deadly mutant KRAS-driven malignancy and may be applicable to other common cancers with KRAS mutations.